Bristol Myers Squibb (CELG-RI) Inventory Average (2009 - 2026)
Bristol Myers Squibb (CELG-RI) reported Inventory Average of $2.7 billion for Q1 2026, up 4.27% year-over-year from $2.6 billion in Q1 2025, and little changed quarter-over-quarter from $2.7 billion in Q4 2025.
Bristol Myers Squibb (CELG-RI) Inventory Average (2009 - 2026) Analysis & Trends
Bristol Myers Squibb (CELG-RI) has 17 years of Inventory Average data on file, last reported at $2.7 billion in Q1 2026.
- Inventory Average for Q1 2026 came in at $2.7 billion, up 4.27% year-over-year; the trailing twelve-month figure through Mar 2026 was $2.7 billion (up 4.27% YoY), and the FY2025 annual result was $2.6 billion, up 0.54% from the prior year.
- Inventory Average was little changed at $2.7 billion in Q1 2026 per CELG-RI's latest filing, from $2.7 billion in the prior quarter.
- Over five years, Inventory Average peaked at $3.2 billion in Q3 2024 and troughed at $2.1 billion in Q1 2022.
- A 5-year average of $2.6 billion and a median of $2.6 billion in 2025 frame the typical range for Inventory Average.
- The sharpest annual moves came in 2024 and 2025: Inventory Average jumped 33.52% in 2024, then decreased 14.26% in 2025.
- A 5-year view of Inventory Average shows it stood at $2.2 billion in 2022, then climbed by 15.52% to $2.5 billion in 2023, then increased by 15.52% to $2.9 billion in 2024, then fell by 7.49% to $2.7 billion in 2025, then decreased by 0.04% to $2.7 billion in 2026.
- Business Quant data shows CELG-RI's Inventory Average at $2.7 billion in Q1 2026, $2.7 billion in Q4 2025, and $2.7 billion in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Inventory Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Gsk | 93,699,046.73 Bn | 93,699,041.77 Bn | 7.76 Bn | 8.09 Bn |
| 2 | Eli Lilly | 1,012.06 Bn | 1,006.77 Bn | 16.22 Bn | 14.14 Bn |
| 3 | Johnson & Johnson | 560.67 Bn | 538.62 Bn | 15.96 Bn | 14.39 Bn |
| 4 | AbbVie | 402.20 Bn | 392.85 Bn | 10.78 Bn | 5.00 Bn |
| 5 | Merck | 298.59 Bn | 292.94 Bn | 12.09 Bn | 6.57 Bn |
| 6 | Amgen | 188.77 Bn | 176.74 Bn | 5.87 Bn | 6.21 Bn |
| 7 | Gilead Sciences | 160.22 Bn | 152.49 Bn | 5.52 Bn | 1.84 Bn |
| 8 | Pfizer | 148.19 Bn | 135.42 Bn | -1.21 Bn | 10.66 Bn |
| 9 | Bristol Myers Squibb | 116.72 Bn | 106.26 Bn | 8.07 Bn | 2.72 Bn |
| 10 | Bristol Myers Squibb | - | - | 8.07 Bn | 2.72 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 2.72 Bn |
| Dec 31, 2025 | 2.72 Bn |
| Sep 30, 2025 | 2.75 Bn |
| Jun 30, 2025 | 2.70 Bn |
| Mar 31, 2025 | 2.61 Bn |
| Dec 31, 2024 | 2.94 Bn |
| Sep 30, 2024 | 3.20 Bn |
| Jun 30, 2024 | 3.03 Bn |
| Mar 31, 2024 | 2.82 Bn |
| Dec 31, 2023 | 2.55 Bn |
| Sep 30, 2023 | 2.40 Bn |
| Jun 30, 2023 | 2.48 Bn |
| Mar 31, 2023 | 2.47 Bn |
| Dec 31, 2022 | 2.21 Bn |
| Sep 30, 2022 | 2.11 Bn |
| Jun 30, 2022 | 2.12 Bn |
| Mar 31, 2022 | 2.10 Bn |
| Dec 31, 2021 | 2.13 Bn |
| Sep 30, 2021 | 2.15 Bn |
| Jun 30, 2021 | 2.05 Bn |